Private Trust Co. NA Has $100,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Private Trust Co. NA raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 16.5% in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 191 shares of the biopharmaceutical company’s stock after acquiring an additional 27 shares during the period. Private Trust Co. NA’s holdings in Regeneron Pharmaceuticals were worth $100,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in REGN. Creative Financial Designs Inc. ADV increased its holdings in Regeneron Pharmaceuticals by 9.5% in the first quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company’s stock valued at $139,000 after purchasing an additional 19 shares during the last quarter. Proficio Capital Partners LLC grew its position in shares of Regeneron Pharmaceuticals by 6.2% during the 1st quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company’s stock worth $207,000 after buying an additional 19 shares during the period. Cove Private Wealth LLC increased its stake in shares of Regeneron Pharmaceuticals by 4.5% in the 1st quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 20 shares during the last quarter. Marino Stram & Associates LLC raised its position in shares of Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after acquiring an additional 20 shares during the period. Finally, Activest Wealth Management boosted its stake in Regeneron Pharmaceuticals by 110.5% during the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 21 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $584.74 on Thursday. The company has a fifty day moving average price of $576.17 and a 200 day moving average price of $562.42. The firm has a market cap of $61.98 billion, a PE ratio of 14.74, a PEG ratio of 1.81 and a beta of 0.31. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $959.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter last year, the business posted $11.56 EPS. Research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Analyst Upgrades and Downgrades

REGN has been the subject of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday, October 14th. Sanford C. Bernstein boosted their price target on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the company an “outperform” rating in a report on Wednesday, August 27th. Citigroup upped their price objective on shares of Regeneron Pharmaceuticals from $650.00 to $660.00 and gave the company a “buy” rating in a research report on Monday, October 13th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 8th. Finally, Morgan Stanley decreased their target price on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $817.88.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.